BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders.
+ 1 more risk
Flawless balance sheet with limited growth.
Share Price & News
How has BELLUS Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BLU's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BLU underperformed the Canadian Biotechs industry which returned 45.5% over the past year.
Return vs Market: BLU underperformed the Canadian Market which returned -12.4% over the past year.
Price Volatility Vs. Market
How volatile is BELLUS Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHere's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation
1 month ago | Simply Wall StBELLUS Health Inc. (TSE:BLU) Just Reported And Analysts Have Been Cutting Their Estimates
2 months ago | Simply Wall StHave Insiders Been Buying BELLUS Health Inc. (TSE:BLU) Shares This Year?
Is BELLUS Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BLU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BLU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BLU is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BLU is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLU is good value based on its PB Ratio (2.2x) compared to the CA Biotechs industry average (5.3x).
How is BELLUS Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLU's revenue (114.8% per year) is forecast to grow faster than the Canadian market (5.5% per year).
High Growth Revenue: BLU's revenue (114.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BLU is forecast to be unprofitable in 3 years.
How has BELLUS Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLU is currently unprofitable.
Growing Profit Margin: BLU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BLU is unprofitable, and losses have increased over the past 5 years at a rate of -76.4% per year.
Accelerating Growth: Unable to compare BLU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: BLU has a negative Return on Equity (-24.35%), as it is currently unprofitable.
How is BELLUS Health's financial position?
Financial Position Analysis
Short Term Liabilities: BLU's short term assets ($81.6M) exceed its short term liabilities ($5.3M).
Long Term Liabilities: BLU's short term assets ($81.6M) exceed its long term liabilities ($9.0K).
Debt to Equity History and Analysis
Debt Level: BLU is debt free.
Reducing Debt: BLU had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BLU has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 41.2% each year.
What is BELLUS Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLU's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roberto Bellini (40yo)
Mr. Roberto Bellini has been the Chief Executive Officer and President of BELLUS Health Inc, since January 1, 2010. Mr. Bellini served as an Executive Vice President of Picchio Pharma Inc. until January 1, ...
CEO Compensation Analysis
Compensation vs Market: Roberto's total compensation ($USD1.64M) is about average for companies of similar size in the Canadian market ($USD1.63M).
Compensation vs Earnings: Roberto's compensation has increased whilst the company is unprofitable.
|Vice President of Finance||11yrs||US$584.78k||0.014% $136.5k|
|Senior Vice President of Drug Development||15.5yrs||US$834.13k||0.0011% $11.1k|
|Chief Medical Officer||0.92yr||US$3.52m||no data|
|Vice President of Business Development||8.42yrs||US$617.21k||no data|
|Director of Investor Relations & Communications||no data||no data||no data|
|Corporate Secretary||9.42yrs||no data||0.0027% $26.5k|
Experienced Management: BLU's management team is seasoned and experienced (10 years average tenure).
|Chairman of the Board||no data||US$458.48k||0.58% $5.7m|
|Independent Director||10.17yrs||US$156.74k||0.86% $8.5m|
|Independent Director||11.5yrs||US$169.24k||no data|
|Independent Director||2.83yrs||US$149.24k||0.031% $301.7k|
|Independent Director||3.17yrs||US$156.74k||0.18% $1.8m|
|Independent Lead Director||no data||US$201.74k||0.13% $1.3m|
|Member of Clinical Advisory Board||1.83yrs||no data||no data|
|Chairman of the Clinical Advisory Board||1.83yrs||no data||no data|
|Member of Clinical Advisory Board||1.83yrs||no data||no data|
Experienced Board: BLU's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BLU insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.1%.
BELLUS Health Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BELLUS Health Inc.
- Ticker: BLU
- Exchange: TSX
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$987.517m
- Shares outstanding: 60.29m
- Website: https://www.bellushealth.com
Number of Employees
- BELLUS Health Inc.
- 275 Armand-Frappier Boulevard
- H7V 4A7
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BHN0||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 2000|
|BLU||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Jun 2000|
|BLU||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Jun 2000|
|0UL1||LSE (London Stock Exchange)||Yes||Common Shares||GB||CAD||Jun 2000|
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/07 00:00|
|End of Day Share Price||2020/07/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.